To Stent or not to Stent? A Review of the Evidence on the Utility of Stenting in Renal Artery Stenosis

November 22, 2013

By Elizabeth Hammer, MD

Faculty Peer Reviewed

Renovascular hypertension, often caused by renal artery stenosis (RAS) due to atherosclerosis or fibromuscular dysplasia, is the most common potentially correctable cause of secondary hypertension. Although only approximately one percent of patients with hypertension have atherosclerotic renovascular disease (ARVD), the prevalence increases to 30-40% in patients with CAD, CHF, and PVD. Screening studies of asymptomatic populations in the United States demonstrate a disease prevalence of 7%, with an annual incidence of 0.5% per year in analyses of medical claims of asymptomatic patients over age 65 [1]. Moreover, ARVD has been found to significantly increase cardiovascular morbidity and mortality; in a recent randomized controlled trial, annual mortality was 8% in patients with ARVD as compared with 3.7% in the general population [1]. As such, this article will focus on management of RAS due to atherosclerosis in particular.

Currently there are three treatment options: (1) medical therapy, consisting of statins, anti-platelet agents, and blood pressure control with renin-angiotensin blockade; (2) percutaneous transluminal renal angioplasty with stent placement (PTRAS); and (3) surgical revascularization. Testing for ARVD is not without risk, especially in those with impaired kidney function. Additionally, procedures to correct RAS are associated with morbidity and mortality, including renal artery dissection, thrombosis, or perforation, acute kidney injury, and death. According to the 2005 American College of Cardiology/American Heart Association guidelines [2], then, testing for RAS is indicated only in those with a suggestive history and in whom a corrective procedure will be performed if ARVD is detected. Therein lies the major question: is stenting worthwhile in the treatment of RAS? More specifically, does percutaneous angioplasty deliver improvements in blood pressure control, renal disease, and cardiovascular outcomes that cannot be obtained by medication alone?

Although many studies have attempted to answer these questions, the findings thus far are unsettling. Upon review of the relevant research, a wide discrepancy emerges between the outcomes from observational data versus those obtained from randomized controlled trials. Observational data have demonstrated a clear benefit from stenting in patients with ARVD. Grey et al [3] found a significant decrease in blood pressure, serum creatinine, New York Heart Association functional class, and number of annual hospitalizations for heart failure in 39 patients who had undergone PTRAS for refractory heart failure. Similarly, Kalra [4] reported significantly lower rates of mortality and renal disease progression in 89 patients treated with PTRAS in comparison with 346 patients treated with medical therapy alone. Additionally, systematic reviews of multiple observational cohort studies have consistently found that PTRAS is associated with improvement in blood pressure and kidney function [5].

Yet these impressive positive effects have failed to withstand more rigorous investigation. The three earliest RCTs from 1998 to 2000 [6,7,8] failed to show improvement in blood pressure with procedural intervention as compared with medical therapy alone. It should be noted that the external validity of these studies is limited. In these trials, balloon angioplasty was performed without stent placement, a practice that has since been associated with worse angiographic outcomes and higher rates of re-stenosis, and one which is therefore no longer standard of care. Additionally, these studies have been criticized for their small sample sizes, short follow up times, high cross-over rates, and inclusion of patients with clinically insignificant stenosis.

Despite the limitations of these earliest RCTs, their findings – namely a lack of benefit with stenting as compared with medical therapy- appear to be validated in subsequent RCTs and meta-analyses. The STAR trial [9] enrolled 140 patients with RAS >50% and renal insufficiency and found that PTRAS did not improve creatinine clearance or secondary endpoints of cardiovascular morbidity and mortality. In the largest trial to date, ASTRAL [10], 806 patients with RAS >50% were randomized to PTRAS versus medical therapy alone. Not only did stenting fail to demonstrate benefit in terms of the primary endpoint of loss of renal function and secondary endpoints of blood pressure, cardiovascular events, and all-cause mortality, but also the rate of serious adverse events with stenting was 6.8%. Unsurprisingly then, a meta-analyses by Kumbhani et al [11] of the various RCTs failed to demonstrate any difference between PTRAS and drug therapy in terms of blood pressure control, renal function, all cause mortality, heart failure, and stroke. Additional meta-analysis by Pierdeomenico et al [12] also failed to show any difference in the risk of future nonfatal myocardial infarction.

However, neither one of the above RCTs is above reproach, specifically with regards to patient selection. Approximately 28% of patients randomized to PTRAS in the STAR trial [9] did not get stented because they were noted to have insignificant (less than 50%) stenosis when angiogram for stent placement was performed. And in the ASTRAL trial [10], patients were included only if their primary treating physician was uncertain whether the patient would definitely benefit from revascularization, thereby likely excluding high-risk patients.

So what conclusions can we draw? Well, here are my parting thoughts:

1. Most patients should be managed with drug therapy alone. The preponderance of the most rigorous type of evidence from RCTs clearly demonstrates the risk of harm without clear demonstrable benefit from revascularization.

2. More research is needed on the utility of revascularization in high-risk patients. It is possible that the discrepancy between outcomes in the observational trials and RCTs is due to the fact that high-risk patients derive benefit from PTRAS whereas low to moderate risk patients or patients with incidental finding of RAS on imaging, the majority of patients studied, do not.

The ongoing CORAL trial [13] – whose results are due imminently – should shed some light on these issues. This prospective, multicenter, un-blinded randomized controlled trial aims to determine the incremental value of stent revascularization in addition to optimal medical therapy. Potential subjects all underwent renal angiogram and were included in the study if they had atherosclerotic renal stenosis >80% or >60% with a 20mmHg systolic pressure gradient as well as systolic hypertension of at least 155 on a minimum of two anti-hypertensive agents. 1,080 subjects were randomized with a 90% power to detect a 28% reduction in the composite endpoint of cardiovascular or renal death, MI, hospitalization for CHF, stroke, doubling of creatinine, and need for renal replacement therapy. The results of this study are expected to provide more definitive guidance, so stay tuned.

3. Current AHA/ACC guidelines [2] suggest that revascularization be considered only in those with a high likelihood of benefit from undergoing stenting, namely those with short duration of blood pressure elevation prior to diagnosis of ARVD, failure of optimal medical therapy to control blood pressure, intolerance to optimal medical therapy, and recurrent flash pulmonary edema and/or refractory heart failure.

Dr. Elizabeth Hammer is a 2nd-year resident at NYU Langone Medical Center

Peer reviewed by David Goldfarb, MD, Professor of Medicine, Department of Medicine (Nephrology),  NYU Langone Medical Center and Chief of Nephrology at the Department of Veterans Affairs New York Harbor.

Image courtesy of Wikimedia Commons

References

1. Ritchie J, Green D, Kalra PA. Current views on the management of atherosclerotic renovascular disease. Ann Intern Med 2012; 44(supp1): S98.  http://www.ncbi.nlm.nih.gov/pubmed/22713155

2. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabiitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463

3. Gray BH, Olin JW, Childs MB, et al. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med 2002; 7:275.

4. Kalra PA, Chrysochou C, Green D, et al. The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease. Catheter Cardiovasc Interv 2010; 75:1.  https://www.ncbi.nlm.nih.gov/m/pubmed/19937777/

5. Foy A, Ruggiero NJ, Filippone. Revascularization in renal artery stenosis. Cardiology in Review 2012; 20:189.  http://www.ncbi.nlm.nih.gov/pubmed/22314144

6. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments v Angioplastie (EMMA) Study Group. Hypertension 1998; 31:823.

7. Webster J, Marshall F, Abdalla M, et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998; 12:329.

8. van Jaarsveld BC, Krinjen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000; 342:1007.

9. Bax L, Woittiez AJ, Kouwenberg HJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: as randomized trial. Ann Intern Med 2009; 150:840.  http://www.ncbi.nlm.nih.gov/pubmed/19414832

10. ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361:1953.

11. Kumbhani DJ, Bavry AA, Harvey JE, et al. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. Am Heart J 2011; 161:622. http://www.ncbi.nlm.nih.gov/pubmed/21392620

12. Pierdomenico AD, Pierdomenico AM, Cuccurullo C, et al. Cardiac events in hypertensive patients with renal artery stenosis treated with renal angioplasty or drug therapy: meta-analysis of randomized trials. Am J Hypertension 2012; 25:1209.

13. Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rational and design of the CORAL trail. American Heart Journal 2006; 152:59.  http://www.ncbi.nlm.nih.gov/pubmed/16824832

 

 

 

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

*